Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23948510 | 0.79 | TNKS2 (0.37) | MEN1ALDH1A1LMNAHPGDKMT2A | |
| SCHEMBL23948511 | 0.79 | CHRM2 (0.38) | TSHR | |
| SCHEMBL20570855 | 0.75 | RXFP1 (0.41) | ALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL23948590 | 0.75 | TAAR1 (0.39) | MEN1ALDH1A1LMNAHPGDKMT2A | |
| SCHEMBL25827883 | 0.75 | ALDH1A1 (0.43) | MEN1ALDH1A1LMNAHPGDKMT2A | |
| Acetic Acid SCHEMBL23925788 | 0.75 | ACHE (0.36) | TSHR | |
| SCHEMBL20570535 | 0.74 | HPGD (0.46) | ALDH1A1LMNAHPGDKMT2ATSHR | |
| SCHEMBL30390536 | 0.72 | HMGCR (0.37) | MEN1ALDH1A1LMNAHPGDKMT2A | |
| SCHEMBL23948509 | 0.71 | TDP1 (0.52) | MEN1ALDH1A1HPGDKMT2AHSD17B10 | |
| SCHEMBL3342032 | 0.71 | PTGS2 (0.37) | MEN1ALDH1A1LMNAHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11701427-B2 | Diels-alder conjugation methods | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2021211984-A1 | DIELS-ALDER CONJUGATION METHODS | REGENERON PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207412-A1 | DIELS-ALDER CONJUGATION METHODS | GLUL, TGM2, GLS | MEN1 613/4885ALDH1A1 74/4885LMNA 2896/4885 |
| US-11701427-B2 | Diels-alder conjugation methods | GLUL, TGM2, GLS | MEN1 613/4885ALDH1A1 74/4885LMNA 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.